FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time
The author describes how providing appropriate information about the API in the Common Technical Document can aid FDA's review of an abbreviated new drug application.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 63-66

References

1. R. Giralt, "A New Definition for API Starting Materials," Pharmaceutical Technology Europe 16 (6), 2004.

2. ICH, Q11: Development and Manufacture of Drug Substances (ICH, May 2011).

3. ICH Q9, Quality Risk Management (ICH, June 2006). This is directly applicable to the drug product manufacture but also applies the risk-based thinking with regard to the drug substance.

4. Muller et al., "A Rationale for Determining, Testing, and Controlling Specific Impurities in Pharmaceuticals that Possess Potential for Genotoxicity," Regulatory Toxicology and Pharmacology 44, 198–211, (2006).

5. A. Thayer, "Genotoxic Impurities," C&E News Sept. 2010, 88 (39), pp. 16–26.

6. FDA, Draft Guidance for Industry: Fermentation Derived Intermediates, Drug Substances, and Related Drug Products (FDA, Dec. 2002)

7. S. Schaeffer, "Equivalence Test Case," Biocentury 18 (34), A1–A7 (2010).

8. ICH, Q8(R2) "Quality Target Product Profile" definition; see also Spring 2011 GPHA Meeting Slides by R. Lionberger; Yu, Pharm. Res. 25 781–791, 2008.

Disclaimer

The views and opinions in this article are only those of the author and do not necessarily reflect the views or policies of the US Food and Drug Administration.

Acknowledgments

The author thanks Naiqi Ya, Dave Skanchy, Bob Iser, and Aloka Srinivasan for their scientific input.

Barbara Scott is a chemistry and manufacturing reviewer (CMC) at the Office of Generic Drugs within the Office of Pharmaceutical Science, under the US Food and Drug Administration's Center for Drug Evaluation and Research,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here